Perampanel · Fycompa
Small molecule
Evidence outlook
Approved: Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs
- Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
- FYCOMPA (perampanel) tablets are indicated as: • adjunctive therapy in the management of partial-onset seizures in patients 7 years of age and older who are not satisfactorily controlled with conventional therapy. • adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients 12 years of age and older with epilepsy, who are not satisfactorily controlled with conventional therapy.
Development in Parkinson's Disease stopped for reasons the sponsor has not stated. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02849626 NCT02849626 · Partial-Onset or Primary Generalized Tonic-Clonic Seizures The study was a single-group, open-label trial with 180 participants and no placebo or active comparator, so it could not provide a controlled statistical comparison of perampanel's effects. Its primary outcomes were safety measures, including adverse events, laboratory values, vital signs, and ECG findings, rather than a controlled clinical efficacy endpoint. Registry: NCT02849626 | 3 | Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase and Extension Phase A of This Study (Baseline up to 4 weeks (follow up in Extension Phase A) after last dose of study drug in Extension Phase A at Week 52 (up to 56 weeks)); Percentage of Participants With Treatment Emergent Markedly Abnormal Laboratory Values for Total Group of Participants- Core Phase and Extension Phase A of This Study (Baseline up to 52 weeks); Percentage of Participants With Abnormal Vital Sign Values for Total Group of Participants- Core Phase and Extension Phase A of This Study (Baseline up to 52 weeks); Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Parameters for Total Group of Participants- Core Phase and Extension Phase A of This Study (Baseline up to 52 weeks) 2019-02-05 | Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase and Extension Phase A of This Study (Baseline up to 4 weeks (follow up in Extension Phase A) after last dose of study drug in Extension Phase A at Week 52 (up to 56 weeks)): Perampanel 0.5 mg/mL: All Participants — Treatment Emergent AEs: 90 percentage of participants; Treatment Emergent SAEs: 20 percentage of participants | Weak signal | link ↗ |
View 5 more trials
NCT03201900 NCT03201900 · Partial Onset Seizures The study was a single-arm, open-label trial without randomization, blinding, or a comparator arm, involving 91 enrolled participants. Its primary clinical endpoint was seizure freedom during 26 weeks of maintenance treatment, but the uncontrolled design does not establish whether perampanel caused the observed result. Registry: NCT03201900 | 3 | Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel (26 weeks in Maintenance Period of 4 mg perampanel) 2019-02-28 | Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel (26 weeks in Maintenance Period of 4 mg perampanel): Perampanel 63% (95% CI 50.9 to 74) | Weak signal | link ↗ |
NCT00699972 NCT00699972 · Epilepsy Registry: NCT00699972 | 3 | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) (Baseline (Pre-randomization) through Week 19) 2010-10-19 | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) (Baseline (Pre-randomization) through Week 19): Placebo -20.95 Percent Change in seizure frequency (range -100 to 397.5) | Perampanel 8mg -26.34 Percent Change in seizure frequency (range -100 to 150.7) | Perampanel 12mg -34.49 Percent Change in seizure frequency (range -100 to 659.7) | not yet graded | link ↗ |
NCT00699582 NCT00699582 · Epilepsy This was a randomized, double-blind, placebo-controlled phase 3 trial of 389 patients, and its primary endpoint, the change in seizure frequency, was met for both perampanel doses. The evidence is rated below the top level because no power calculation was found in the sources checked and the 12 mg group randomized 121 patients against a registered target of 125 per group. Registry: NCT00699582 | 3 | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) (Baseline (Pre-randomization) through Week 19) 2010-12 | Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013). | Partial signal | link ↗ |
NCT00700310 NCT00700310 · Epilepsy This was a randomized, double-blind, placebo-controlled phase 3 trial of 712 patients. Its primary endpoint, the change in seizure frequency, was met for the 4 mg and 8 mg doses but not for the 2 mg dose, so the result across the tested doses is mixed. Registry: NCT00700310 | 3 | Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) (Baseline (Pre-randomization) through Week 19) 2009-08 | Median percent change in seizure frequency: placebo -10.7%, perampanel 2 mg -13.6% (not significant), 4 mg -23.3% (p=0.0026), 8 mg -30.8% (p<0.0001) (Study 306, Neurology 2012). | Partial signal | link ↗ |
NCT01393743 NCT01393743 · Epilepsy This was a randomized, double-blind, placebo-controlled phase 3 trial of 163 patients with a power calculation reported in its publication. Both core-study primary endpoints were met: the reduction in tonic-clonic seizure frequency (median difference -30.8 percentage points, p=0.0001) and the 50% responder rate (64.2% vs 39.5%, p=0.0019). Registry: NCT01393743 | 3 | Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to Baseline (Prerandomization) - (for Core Study) (Baseline (4 or 8 weeks), Titration (4 weeks), and Maintenance (13 weeks)); 50% Responder Rate for Primary Generalized Tonic Clonic Seizure During Maintenance - LOCF - (for Core Study) (Baseline (4 or 8 weeks) and Maintenance (13 weeks)); 50% Responder Rate in Primary Generalized Tonic-Clonic Seizure Frequency Per 28 Days Relative to the Core Study Prerandomization Phase - (for Extension Phase) (Week 1 of perampanel treatment to date of last dose of perampanel in the Extension Phase) 2014-05 | Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (25)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Perampanel (Fycompa): this drug | Approved | Small molecule | AMPA receptor (antagonist) | Weak signal | NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results). NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013). | |
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | Partial signal | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Partial signal | NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Carbamazepine | Approved | Small molecule | Sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | Weak signal | NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8) NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Diastat) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eslicarbazepine Acetate (Aptiom) | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed | |
| Ethosuximide | Approved | Small molecule | T-type calcium channel | Reliable signal | NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted. | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | Reliable signal | NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses. | |
| Felbamate | Approved | Small molecule | NMDA receptor (glycine site, antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Fosphenytoin | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | No reviewed efficacy summary in this indication | |
| Gabapentin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Partial signal | NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms. NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed | |
| Lacosamide (Vimpat) | Approved | Small molecule | Voltage-gated sodium channels | Reliable signal | NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001). NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure). | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20 | |
| Levetiracetam (Elepsia XR) | ApprovedUS marketing discontinued | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | not yet graded | No reviewed efficacy summary in this indication | |
| Levetiracetam (Keppra XR) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | Featured results are non-efficacy only in this race | |
| Levetiracetam (Keppra) | Approved | Small molecule | Synaptic vesicle protein 2A (SV2A) | Partial signal | NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6) NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002). | |
| Lorazepam | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Midazolam (Nayzilam) | Approved | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | Reliable signal | NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed | |
| Oxcarbazepine (Oxtellar XR) | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | Featured results are non-efficacy only in this race | |
| Oxcarbazepine (Trileptal) | Approved | Small molecule | Voltage-gated sodium channel | Weak signal | NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. | |
| Phenobarbital Sodium Injection (Sezaby) | Approved | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Phenytoin | Approved | Small molecule | Voltage-gated sodium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | Weak signal | NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed | |
| Primidone | Approved | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). | |
| Stiripentol | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Tiagabine | Approved | Small molecule | GABA transporter (uptake carrier) | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Reliable signal | NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group. | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | Partial signal | NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | Partial signal | NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Zonisamide (Zonegran) | Approved | Small molecule | Voltage-gated sodium channels | Weak signal | Featured results are non-efficacy only in this race | |
| Zonisamide (Zonisade) | Approved | Small molecule | Voltage-gated sodium and T-type calcium channels | not yet graded | No reviewed efficacy summary in this indication | |
| Azetukalner | Phase 3 | Small molecule | Kv7 potassium channel | Reliable signal | NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% | |
| Bexicaserin | Phase 3 | Small molecule | Serotonin 5-HT2C receptor (agonist) | Partial signal | NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed | |
| Carisbamate | Phase 3 | Small molecule | Voltage-gated sodium channel | Partial signal | NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed | |
| Clemizole (EPX-100) | Phase 3 | Small molecule | Histamine H1 receptor, Serotonin receptors (5-HT) | not yet graded | No reviewed efficacy summary in this indication | |
| Diazepam (Libervant) | Phase 3 | Small molecule | GABA-A receptor | Weak signal | Featured results are safety only in this race | |
| Elsunersen | Phase 3 | RNA / oligonucleotide | SCN2A (antisense knockdown) | Partial signal | NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06). | |
| RAP-219 | Phase 3 | Small molecule | AMPA receptor (TARP γ8-dependent) | Weak signal | NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001) | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| Staccato Alprazolam | Phase 3 | Small molecule | GABA-A receptor | Reliable signal | NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) | |
| Vormatrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (NaV1.2 / NaV1.6) | Partial signal | NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed | |
| YCJ-01 | Phase 3 | Botanical | Cannabinoids (full-spectrum cannabis extract) | not yet graded | No reviewed efficacy summary in this indication | |
| Cannabidiol (JZP926) | Phase 2/3 | Small molecule | Cannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoid | not yet graded | No reviewed efficacy summary in this indication | |
| Opakalim | Phase 2/3 | Small molecule | Kv7 potassium channel | Weak signal | NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). | |
| ABS-1230 | Phase 2 | Small molecule | KCNT1 (KNa1.1/Slack) channel | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fycompa (Perampanel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.